PMID

Data

Article Title

Organization

a-Conotoxin [S9A]TxID Potently Discriminates betweena3ß4 anda6/a3ß4 Nicotinic Acetylcholine Receptors.

Hainan University

BMS-933043, a Selectivea7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia.

Bristol-Myers Squibb

Design and synthesis of a novel series of 4-heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes asa7 nicotinic receptor agonists 2. Development of 4-heteroaryl SAR.

Bristol-Myers Squibb Pharmaceutical Research Institute

Design and Synthesis of a New Series of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes asa7 Nicotinic Receptor Agonists. 1. Development of Pharmacophore and Early Structure-Activity Relationship.

Bristol-Myers Squibb

Bis(ammonio)alkane-type agonists of muscarinic acetylcholine receptors: synthesis, in vitro functional characterization, and in vivo evaluation of their analgesic activity.

Universit£

Characterization of a novela-conotoxin TxID from Conus textile that potently blocks rata3ß4 nicotinic acetylcholine receptors.

Hainan University

Random chemistry as a new tool for the generation of small compound libraries: development of a new acetylcholinesterase inhibitor.

University of WüRzburg

Development of novel 2-aminoalkyl-6-(2-hydroxyphenyl)pyridazin-3(2H)-one derivatives as balanced multifunctional agents against Alzheimer's disease.

Guizhou Medical University

Computational and Functional Mapping of Human and Rat ?6?4 Nicotinic Acetylcholine Receptors Reveals Species-Specific Ligand-Binding Motifs.

Veterans Affairs Medical Center

Development of the "hidden" multifunctional agents for Alzheimer's disease.

Zhejiang Academy of Medical Sciences

Triazole derivatives as inhibitors of Alzheimer's disease: Current developments and structure-activity relationships.

Wuhan Institute of Technology

Peptide therapeutics from venom: Current status and potential.

Peptides International